JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alauddin, M. M.
Right arrow Articles by Conti, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alauddin, M. M.
Right arrow Articles by Conti, P. S.
Journal of Nuclear Medicine Vol. 45 No. 12 2063-2069
© 2004 by Society of Nuclear Medicine


Basic Science Investigations

Synthesis and Evaluation of 2'-Deoxy-2'-18F-Fluoro-5-Fluoro-1-ß-D-Arabinofuranosyluracil as a Potential PET Imaging Agent for Suicide Gene Expression

Mian M. Alauddin, PhD, Antranic Shahinian, BS, Ryan Park, BS, Michel Tohme, MS, John D. Fissekis, PhD and Peter S. Conti, MD, PhD

PET Imaging Science Center, Department of Radiology, University of Southern California, Los Angeles, California

2'-Deoxy-2'-18F-fluoro-5-fluoro-1-ß-D-arabinofuranosyluracil (18F-FFAU) has been synthesized and evaluated in HT-29 cells as a potential PET agent for herpes simplex virus type 1 thymidine kinase (HSV1-tk) gene expression. Methods: 2-Deoxy-2-18F-fluoro-1,3,5-tri-O-benzoyl-{alpha}-D-arabinofuranose was prepared by the reaction of the respective 2-triflate with tetrabutylammonium 18F-fluoride. The fluorosugar was converted to its 1-bromo derivative and coupled with protected 5-fluorouracil. The crude product was hydrolyzed in base and purified by high-performance liquid chromatography to obtain the 18F-FFAU. In vitro studies were performed in HT-29 cells by incubation at various time points. In vivo studies including biodistribution and microPET were performed in tumor-bearing nude mice. Results: The radiochemical yield was 20%–30% decay corrected with an average of 25% in 4 runs. Radiochemical purity was >99% and average specific activity was 85 GBq/µmol (2,300 mCi/µmol) (end of synthesis). In vitro accumulation of 3H-FFAU in HSV1-tk–expressing cells was ~180-fold (P < 0.001) higher than that in the wild-type cells between 30 and 120 min. In vivo uptake of 3H-FFAU in HSV1-tk–positive tumors at 2 h was ~8-fold (P < 0.001) higher than that in the control tumors. Tumor uptake (percentage injected dose per gram of tissue) and the uptake ratio (tk-positive to wild type) of 3H-FFAU in tk-positive cells was higher compared with those of our earlier studies using 2'-14C-deoxy-2'-fluoro-5-methyl-1-ß-D-arabinofuranosyluracil (14C-FMAU) and 9-(4-18F-fluoro-3-hydroxymethylbutyl)guanine (18F-FHBG) in the same cell lines. microPET on tumor-bearing nude mice also demonstrated a very high uptake of 18F-FFAU in tk-positive tumors compared with that of the control tumor without significant accumulation in other organs. Conclusion: These results demonstrate that 18F-FFAU has superior biodistribution characteristics and significantly higher in vivo uptake in HSV1-tk–expressing tumor compared with previously studied agents.

Key Words: 2'-deoxy-2'-18F-fluoro-5-fluoro-1-ß-D-arabinofuranosyluracil • herpes simplex virus type-1 thymidine kinase • HT-29 cells • PET • gene expression


Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
T. Miyagawa, G. Gogiberidze, I. Serganova, S. Cai, J. A. Balatoni, H. T. Thaler, L. Ageyeva, N. Pillarsetty, R. D. Finn, and R. G. Blasberg
Imaging of HSV-tk Reporter Gene Expression: Comparison Between [18F]FEAU, [18F]FFEAU, and Other Imaging Probes
J. Nucl. Med., April 1, 2008; 49(4): 637 - 648.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Y. Cho, J. Polster, J. M. Engles, J. Hilton, E. H. Abraham, and R. L. Wahl
In Vitro Evaluation of Adenosine 5'-Monophosphate as an Imaging Agent of Tumor Metabolism
J. Nucl. Med., May 1, 2006; 47(5): 837 - 845.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al.
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-C. Hung, W.-P. Deng, W. K. Yang, R.-S. Liu, C.-C. Lee, T.-C. Su, R.-J. Lin, D.-M. Yang, C.-W. Chang, W.-H. Chen, et al.
Mesenchymal Stem Cell Targeting of Microscopic Tumors and Tumor Stroma Development Monitored by Noninvasive In vivo Positron Emission Tomography Imaging
Clin. Cancer Res., November 1, 2005; 11(21): 7749 - 7756.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.